Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar Continuous Infusion With Concurrent Chemoradiotherapy in Esophageal Squamous Cell Cancer
ChiCTR-IPR-16009926Phase 4Not yet recruiting
- Sponsor
- Gansu Cancer Hospital
- Start
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of endostar in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Gansu Cancer Hospital. Primary endpoints: Objective Response Rate and Progression-free Survival. Planned start Jan 2017; status: not yet recruiting.
02
Drugs
endostar
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR-IPR-16009926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16009926.